For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level Mr. Shah Coherent Market Insights Pvt.

Medspas are leading the charge in offering GLP-1 treatments, with 60% of medspas in the U.S. now providing these services, compared to 35% of aesthetic physician offices. Average spend per patient ...

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

Popular medications, such as Ozempic, Mounjaro and Wegovy, are known as GLP-1 agonists as they mimic the natural GLP-1s ...

Highmark Health President and CEO David Holmberg discussed the uncertainties facing the insurance industry, including the ...

Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual ...